Table 1.
Patients’ characteristics (n = 74)
| Characteristics | |
|---|---|
| Age (year), mean ± SD [min-max] | 60 ± 14 [21;80] |
| Sex, n (%) | |
| Female | 35 (47.3)% |
| Male | 39 (52.7)% |
| Age-adjusted IPI, n (%) | |
| 0 | 8 (10.8)% |
| 1 | 28 (37.8)% |
| 2 | 24 (32.4)% |
| 3 | 14 (19.0)% |
| Deauville score at i-PET/CT, n (%) | |
| 1 | 23 (31.1)% |
| 2 | 13 (17.6)% |
| 3 | 11 (14.9)% |
| 4 | 13 (17.6)% |
| 5 | 14 (18.9)% |
| Growth factor type (G-CSF), n (%) | |
| Filgrastim | 52 (70.3)% |
| Lenograstim | 10 (13.5)% |
| Pegfilgrastim | 12 (16.2)% |
| First line of chemotherapy, n (%) | |
| R-CHOP | 68 (91.9)% |
| R-ACVBP | 6 (8.1)% |
| Bone involvement*, n (%) | 17 (23.0)% |
| Spleen involvement*, n (%) | 8 (10.8)% |
| Liver involvement*, n (%) | 1 (1.3)% |
| Baseline MATV (cc), mean ± SD | 449.4 (732.0)% |
IPI International Prognostic Index, i-PET/CT interim PET/CT, MATV metabolic active tumour volume
*Based on PET/CT analysis